+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Canavan Disease Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, End User, Therapy Line, Developer Type, Technology, Patient Age Group - Global Forecast 2025-2030- Product Image
Canavan Disease Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, End User, Therapy Line, Developer Type, Technology, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Canavan Disease Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, End User, Therapy Line, Developer Type, Technology, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977903
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Canavan Disease Therapeutics Market is entering a pivotal phase, driven by genetic innovation, expanded industry collaboration, and evolving policy landscapes. Addressing historically unmet needs within the field of leukodystrophies, the market sets the stage for transformative approaches that will influence stakeholders’ resource allocation and commercial strategy.

Market Snapshot: Canavan Disease Therapeutics Market Growth and Trends

In 2024, the Canavan Disease Therapeutics Market was valued at USD 556.66 million, advancing to USD 591.07 million in 2025, with a projected CAGR of 5.95% to reach USD 787.59 million by 2030. Market growth is underpinned by rapid progress in gene therapy, heightened research investments, and regulatory support for rare disease drug development.

Scope & Segmentation

Comprehensive segmentation offers actionable insight into commercial models and future trends:

  • Therapy Type: Enzyme replacement, gene therapy (AAV and lentiviral vectors), small molecule interventions (including lithium and N-acetylcysteine)
  • Route of Administration: Intramuscular, intravenous, oral
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies
  • End User: Clinics, homecare settings, hospitals
  • Therapy Line: First-line, second-line
  • Developer Type: Biotech companies, pharmaceutical companies
  • Technology: CRISPR-Cas9, TALEN, ZFN gene editing platforms
  • Patient Age Group: Adult and pediatric patients
  • Regional Coverage: Americas (notably United States, Canada, Brazil, Mexico, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and more), Asia-Pacific (notably China, India, Japan, Australia, South Korea, Southeast Asia)
  • Key Companies: Ionis Pharmaceuticals, Aspa Therapeutics, Contera Pharma, RegenxBio, Novartis AG, Biogen, Rocket Pharmaceuticals

Key Takeaways: Strategic Insights for Decision-Makers

  • Gene therapy is moving toward clinical reality, supported by improved vector technologies and adaptive regulatory frameworks.
  • Combination approaches are emerging, integrating gene, enzyme, and small molecule therapies to address multiple facets of disease pathology.
  • Segmented delivery methods and channels reflect a shift toward more patient-friendly, accessible treatment options and align with varied end-user environments.
  • Regulatory advances—such as breakthrough designations and pediatric disease vouchers—are creating faster pathways for therapy validation and approval.
  • Collaborative development models between biotech innovators, academic partners, and manufacturers are accelerating discovery and scaling.

Tariff Impact: Navigating Supply Chain Complexity in 2025

Forthcoming United States tariffs are set to impact supply chain agility and raise research and production costs for Canavan disease therapies. Increased duties on vital inputs, such as imported viral vectors and biomanufacturing reagents, pose risks of supply delays and higher operational expenses. Stakeholders are mitigating these headwinds through diversification of supplier bases, localizing manufacturing, and proactive tariff classification assessments, while engaging closely with regulatory and customs authorities to safeguard critical development timelines.

Methodology & Data Sources

This report employs a rigorous methodology, blending primary research—through interviews with leading clinicians, regulators, and advocacy leaders—with systematic secondary analysis of peer-reviewed journals, industry developments, and regulatory guidance. Data validation involved expert workshops and cross-referencing multiple reputable sources to ensure comprehensive and objective market insight.

Why This Report Matters for the Canavan Disease Therapeutics Market

  • Provides clarity on emerging scientific, commercial, and regulatory drivers shaping the Canavan Disease Therapeutics Market.
  • Offers strategic segmentation and actionable insight tailored for executive decision-making and investment prioritization.
  • Equips leadership teams with practical recommendations to optimize partnerships, adapt to supply chain risks, and enhance patient-centric care models.

Conclusion

The Canavan Disease Therapeutics Market stands at a transformative juncture, shaped by advances in gene and enzyme therapies, dynamic regulatory support, and forward-looking alliances. Strategic guidance delivered by this report positions stakeholders to optimize outcomes in an evolving therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in gene therapy clinical trials targeting ASPA gene restoration
5.2. Innovative small molecule compounds focusing on myelin preservation in the central nervous system
5.3. Regulatory review progress of AAV-mediated therapies for rare neurological disorders in FDA fast track programs
5.4. Collaborations between biotech startups and academic institutions for biomarker validation in Canavan disease
5.5. Patient advocacy initiatives driving increased funding and awareness for Canavan disease clinical research
5.6. Application of machine learning algorithms to optimize dosing regimens for enzyme replacement therapy in Canavan disease
5.7. Development of lipid nanoparticle delivery platforms for targeted central nervous system gene transfer in Canavan disease
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Canavan Disease Therapeutics Market, by Therapy Type
8.1. Introduction
8.2. Enzyme Replacement Therapy
8.3. Gene Therapy
8.3.1. Aav Vector
8.3.2. Lentiviral Vector
8.4. Small Molecule Therapy
8.4.1. Lithium
8.4.2. N-Acetylcysteine
9. Canavan Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Oral
10. Canavan Disease Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Canavan Disease Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare Settings
11.4. Hospitals
12. Canavan Disease Therapeutics Market, by Therapy Line
12.1. Introduction
12.2. First-Line
12.3. Second-Line
13. Canavan Disease Therapeutics Market, by Developer Type
13.1. Introduction
13.2. Biotech Companies
13.3. Pharma Companies
14. Canavan Disease Therapeutics Market, by Technology
14.1. Introduction
14.2. Crispr-Cas9
14.3. Talen
14.4. Zfn
15. Canavan Disease Therapeutics Market, by Patient Age Group
15.1. Introduction
15.2. Adult Patients
15.3. Pediatric Patients
16. Americas Canavan Disease Therapeutics Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Canavan Disease Therapeutics Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Canavan Disease Therapeutics Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Ionis Pharmaceuticals, Inc.
19.3.2. Aspa Therapeutics
19.3.3. Contera Pharma
19.3.4. RegenxBio
19.3.5. Novartis AG
19.3.6. Biogen Inc.
19.3.7. Rocket Pharmaceuticals
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. CANAVAN DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. CANAVAN DISEASE THERAPEUTICS MARKET: RESEARCHAI
FIGURE 32. CANAVAN DISEASE THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 33. CANAVAN DISEASE THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 34. CANAVAN DISEASE THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANAVAN DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 123. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 126. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 127. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 128. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 129. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 136. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 137. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 138. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 139. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 140. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 141. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 142. CANADA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 143. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 146. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 156. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 157. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 160. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 161. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. MEXICO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 245. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 246. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 247. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 248. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 249. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 250. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 251. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 258. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 259. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 260. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 261. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 262. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 263. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. GERMANY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 266. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 267. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 268. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 269. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 270. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 271. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 278. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 279. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 280. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 281. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 282. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 283. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 284. FRANCE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 305. ITALY CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-20

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Canavan Disease Therapeutics market report include:
  • Ionis Pharmaceuticals, Inc.
  • Aspa Therapeutics
  • Contera Pharma
  • RegenxBio
  • Novartis AG
  • Biogen Inc.
  • Rocket Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 591.07 Million
Forecasted Market Value ( USD ) by 2030 $ 787.59 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Huntington`s Disease Therapeutics Market by Treatment Type (Antisense Oligonucleotides, Gene Therapy, Small Molecule Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User, Payer Type, Disease Stage - Global Forecast 2025-2030 - Product Image

Huntington`s Disease Therapeutics Market by Treatment Type (Antisense Oligonucleotides, Gene Therapy, Small Molecule Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User, Payer Type, Disease Stage - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Parkinson's Disease Therapeutics Market by Drug Class (Anticholinergics, COMT Inhibitors, Dopamine Agonists), Therapy Type (Medications, Non-Pharmacological Therapies), Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Parkinson's Disease Therapeutics Market by Drug Class (Anticholinergics, COMT Inhibitors, Dopamine Agonists), Therapy Type (Medications, Non-Pharmacological Therapies), Route Of Administration, Targeted Area, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions - Product Image

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions

  • Report
  • 375 Pages
  • Global
From
Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 268 Pages
  • Global
From
Nucleic Acid Based Therapeutics - Global Strategic Business Report - Product Image

Nucleic Acid Based Therapeutics - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From

About the Canavan Disease Drug Market

Canavan Disease is a rare, inherited disorder of the central nervous system caused by a deficiency of the enzyme aspartoacylase. It is characterized by progressive deterioration of the brain, leading to mental and physical disability. Treatment for Canavan Disease is limited to supportive care, and there is currently no approved drug therapy. The Canavan Disease Drug market is a small but growing segment of the Central Nervous System Drugs market. Companies in this market are focused on developing treatments for Canavan Disease, including gene therapy, enzyme replacement therapy, and small molecule drugs. These treatments are still in the early stages of development, and there is no approved drug therapy for Canavan Disease yet. Companies in the Canavan Disease Drug market include Lysogene, Bluebird Bio, and Ultragenyx Pharmaceuticals. Lysogene is developing a gene therapy for Canavan Disease, while Bluebird Bio is developing an enzyme replacement therapy. Ultragenyx Pharmaceuticals is developing a small molecule drug for Canavan Disease. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.